Positive Top-Line Results for bimekizumab in Second Phase 3

/PRNewswire/ -- UCB, a global biopharmaceutical company, today announced positive top-line results from the Phase 3 BE COMPLETE study, which evaluated the...

Related Keywords

Belgium , Boston , Massachusetts , United States , Brussels , Bruxelles Capitale , Nicole Herga , Josephf Merola , Emmanuel Caeymaex , Eimear Obrien , J Clin Pharmacol , Antje Witte , Immunology Solutions , Brand Communications , Twitter , Drug Administration , Health Assessment Questionnaire , Harvard Medical School , American College Of Rheumatology , Health Survey , European Union , Corporate Communications , Source Ucb Inc , American College , Health Assessment Questionnaire Disability Index , Psoriasis Area , Severity Index , Short Form , Physical Component Summary , Minimal Disease Activity , Associate Professor , Executive Vice President , Euronext Brussels , Subjects With Active Psoriatic Arthritis , Rheum Dis Clin North , Ucb , Nc ,